Retinoid X receptor a (RXRa) plays important roles in the malignancy of several cancers such as human prostate tumor, breast cancer, and thyroid tumor. However, its exact functions and molecular mechanisms in cholangiocarcinoma (CCA), a chemoresistant carcinoma with poor prognosis, remain unclear. In this study we found that RXRa was frequently overexpressed in human CCA tissues and CCA cell lines. Downregulation of RXRa led to decreased expression of mitosispromoting factors including cyclin D1and cyclin E, and the proliferating cell nuclear antigen, as well as increased expression of cell cycle inhibitor p21, resulting in inhibition of CCA cell proliferation. Furthermore, RXRa knockdown attenuated the expression of cyclin D1 through suppression of Wnt ⁄ b-catenin signaling. Retinoid X receptor a upregulated proliferating cell nuclear antigen expression through nuclear factor-jB (NF-jB) pathways, paralleled with downregulation of p21. Thus, the Wnt ⁄ b-catenin and NF-jB pathways account for the inhibition of CCA cell growth induced by RXRa downregulation. Retinoid X receptor a plays an important role in proliferation of CCA through simultaneous activation of Wnt ⁄ bcatenin and NF-jB pathways, indicating that RXRa might serve as a potential molecular target for CCA treatment.
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C holangiocarcinoma (CCA) is the second most frequent primary hepatic malignancy, originating from biliary epithelial cells. Recent studies showed that the morbidity and mortality of CCA has been increasing all over the world during the past three decades.
(1) Prognosis of CCA is poor, with a 5-year survival rate <5%. (2, 3) Due to insufficiency of conventional chemotherapy and radiotherapy in improving long-term survival, surgical resection is the only effective therapy for early stage tumors. (4) Therefore, it is urgent to clarify the molecular mechanisms underlying CCA proliferation for development of novel effective therapeutic targets.
The retinoid X receptors (RXRs) are members of the steroid ⁄ thyroid hormone superfamily of nuclear receptors, which are transcription factors that are essential in embryonic development, maintenance of differentiated phenotypes, metabolism, and cell death. (5, 6) There are three RXR subtypes, a, b, and c. Among them, RXRa plays unique and uncharacterized roles in many physiological processes including carcinogenesis. Previous studies showed that RXRa is overexpressed in multiple human cancers such as human prostate tumor, (7) breast cancer, (8) and thyroid tumor. (9) Retinoid X receptor a affected the expression of numerous genes, some of which have been implicated in transcription, signal transduction, protein synthesis, and protein trafficking. (10) Genetic data also indicated that RXRs are involved in the chemopreventive activity of retinoic acid in experimental skin carcinogenesis. (11) Consistently, the oncogenic potential of RXRa has been confirmed. Retinoid X receptor a is essential for the development of acute promyelocytic leukemia. (12) It has been reported that targretin, a synthetic RXR ligand, was recently used for treating persistent or refractory cutaneous T-cell lymphoma, (13) (14) (15) indicating the possibility of targeting RXRa for cancer therapy. However, the expression profile of RXRa in CCA and its roles and mechanisms in CCA growth and survival remain unknown.
In the present study, we show that the expression of RXRa is frequently elevated in human CCA specimens and CCA cell lines. Knockdown of RXRa in CCA cells resulted in remarkable suppression of Wnt ⁄ b-catenin and nuclear factor-jB (NFjB) pathways, leading to inhibition of cell proliferation. Our findings might be helpful for understanding the role of RXRa in the development of CCA.
Materials and Methods
Reagents and antibodies. Wnt3a, BMS345541, DAPI, and MTT were from Sigma-Aldrich (Indianapolis, IN, USA). Fetal calf serum and RPMI-1640 medium were purchased from Gibco (Grand Island, NY, USA). Lipofectamine RNAi MAX, Lipofectamine 2000, stealth-siRNA, goat anti-mouse and antirabbit secondary antibodies conjugated to HRP, and donkey anti-rabbit antibody-Alexa Fluor 647 were purchased from Invitrogen (Carlsbad, CA, USA). Monoclonal antibodies against cyclin A, cyclin B1, cyclin D1, cyclin E, p21, b-actin, and polyclonal antibody against RXRa were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal antibodies against b-catenin and phosphorylated b-catenin were purchased from Cell Signaling Technology (Danvers, MA, USA). The PVDF membranes were obtained from Millipore (Billerica, MA, USA) and the 5-ethynyl-2 0 -deoxyuridine (EdU) assay kit was from RiboBio (Guangzhou, China). The Dual-Glo Luciferase Assay System kit was purchased from Promega (Madison, WI, USA) and the EliVision Plus kit was from Maixin Bio (Fuzhou, China).
Patients and tumor specimens. (16) HCCC9810 and human intrahepatic biliary epithelial cells (HIBEpiC) were purchased from Cell Bank of the Chinese Academy of Sciences (Beijing, China). QBC939, MZ-ChA-1, SK-ChA-1, and HCCC9810 human cholangiocarcinoma cells and HIBEpiC human intrahepatic biliary epithelial cells were cultured in RPMI-1640 supplemented with 10% FBS, 100 U ⁄ mL penicillin, and 100 U ⁄ mL streptomycin at 37°C in an atmosphere of 5% CO 2 . Stealth siRNA (40 nM) targeting RXRa (Invitrogen) and nonspecific Stealth siRNA (siCtrl) (40 nM) were transfected with Lipofectamine RNAi Max (Invitrogen) according to the manufacturer's instructions. Myc-RXRa and pCMV-myc (Ctrl) were transfected with Lipofectamine 2000 according to the manufacturer's instructions.
Cell viability assay. Cells were seeded in 96-well plates and MTT was added to each well. The plates were incubated at 37°C for 4 h, followed by addition of 100 lL DMSO. The absorbance was measured at 490 nm using a microplate reader (Model 680; Bio-Rad, Hercules, CA, USA).
Colony formation. Five hundred cells were cultured in 6-well plates for 2 weeks. The colonies were fixed and stained with 0.005% crystal violet for 30 min and counted.
Cell proliferation assay. 5-Ethynyl-2 0 -deoxyuridine is a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis. Cells were seeded in each well of a 96-well plate, and then transfected with siRNA (40 nM) and siCtrl (40 nM) using Lipofectamine RNAi Max after 24 h. The cells were incubated for 2 h after the addition of 100 lL EdU solution (50 lM), then stained with Apollo. Finally, Hoechst 33342 solution was added to visualize the nuclei. The staining was examined using a Leica TCS SP5 II laser confocal microscope (Leica, Barcelona, Spain).
Immunohistochemistry. Paraffin-embedded human CCA tissue sections were pretreated with blocking buffer (5% normal goat serum in PBS) for 30 min at room temperature, and then immunostained with antibody against RXRa (1:200) at 4°C overnight, followed by incubation with secondary antibody conjugated with HRP. Images were collected and analyzed using an inverted fluorescence microscope. The staining intensity of RXRa protein was categorized into four different grades according to their different positive rates. The staining intensity AE and + were considered as low expression, and ++ and +++ were considered as high expression.
Immunofluorescence. Cells were seeded on glass slides overnight. After siRXR or siCtrl (40 nM) transfection for 24 h, and then Wnt3a (50 ng ⁄ mL) treatment for 6 h, cells were fixed with 4% paraformaldehyde for 15 min, permeabilized using 0.5% Triton X-100 for 20 min, and blocked using normal donkey serum for 30 min. The primary antibodies (b-catenin, 1:200) were added and incubated at 4°C overnight. The slides were washed and incubated with Alexa Fluor 647-conjugated secondary antibodies (1:100) at room temperature for 30 min, then DAPI (1 lg ⁄ mL) was used to stain nuclei. The images were taken under a Leica TCS SP5 II laser confocal microscope using the LSM-510 confocal laser scanning microscope system, as previously described. (17) Quantitative PCR. Total RNA was extracted using a Simple RNA Extraction kit (Tiangen, Beijing, China) according to the manufacturer's instructions. Reverse transcription was carried out using the SuperScript III First-Strand Synthesis System (Invitrogen) for real-time RT-PCR. The RT-PCR was carried out in 96-well plates with the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Relative quantification was analyzed by normalization to the amount of human GAPDH. Primers used for real-time PCR are listed on Table 1 .
Western blot analysis. The concentration of extracted proteins was determined with the BCA Kit (Thermo Scientific Pierce, Rockford, IL, USA). Western blot analysis was carried out as previously described. (18) Equal amounts of protein lysates underwent 10% SDS-PAGE and then were transferred onto a PVDF membrane (Millipore). The membrane was incubated with primary antibodies, followed by incubation with secondary antibody-conjugated HRP and the signal was finally visualized by chemiluminescence (Tiangen).
Flow cytometry. QBC939 cells treated by siRNA (Ctrl or RXRa) for 24 h were harvested, and fixed in 75% ethanol at 4°C overnight. Cells were incubated with RNase A at 37°C for 30 min, and then stained with propidium iodide (SigmaAldrich). Cell cycle was measured by flow cytometry. The data were analyzed with the ModFit 3.3 (Verity Software House, Topsham, ME, USA) software.
Dual-luciferase reporter assay. QBC939, MZ-ChA-1, or HCCC9810 cells (1.0 9 10 4 cells ⁄ well) were seeded in 96-well plates for 24 h before transfection. QBC939 and MZChA-1 cells were transfected with siRNA (RXRa or Ctrl) for 24 h. HCCC9810 cells were transfected with Myc-RXRa and pCMV-myc (Ctrl) for 24 h. Then cells in each well were cotransfected with 100 ng pTOPFlash or pFOPFlash or p65 reporter plasmid and 20 ng Renilla luciferase expression vector using Lipofectamine 2000 for another 24 h and subsequently with Wnt3a (50 ng ⁄ mL) for 6 h or tumor necrosis factor a (TNFa; 10 ng ⁄ mL) for 4 h. The indicated cells were analyzed for luciferase activity by using a Dual-Glo Luciferase Assay System (Promega), according to the manufacturer's instruc- Statistical analysis was carried out using GraphPad Prism 6 (San Diego, CA, USA). The results were expressed as the mean AE SD. The data obtained from at least three independent experiments. Student's t-test and one-way ANOVA were used for comparison of two or more datasets, respectively. P-value <0.05 was considered statistically significant. Representative experiment of three independent experiments is shown. *P < 0.05; **P < 0.01. OD, optical density.
Results
Retinoid X receptor a overexpressed in human CCA tissues and cell lines. To evaluate the expression of RXRa in CCA, immunohistochemistry was carried out to assess RXRa protein levels in a set of 54 tumor tissues and their surrounding noncancerous tissues. The results confirmed that RXRa protein was predominantly present in the cell cytoplasm (Fig. 1a) . The high expression rate of RXRa protein in CCA tissues was 68.5% (37 ⁄ 54) ( Table 2) . Furthermore, RXRa protein predominantly existed in the cytoplasm of CCA cell line QBC939, as shown by the immunofluorescence (IF) results (Fig. 1b) . In addition, the expression of RXRa was significantly increased in CCA cell lines such as QBC939, MZ-ChA-1, and SK-ChA-1 compared with HIBEpiC (Fig. 1c) . These data showed that RXRa is markedly overexpressed in CCA patients as well as in CCA cell lines.
Retinoid X receptor a knockdown inhibits CCA cell proliferation. To investigate the role of RXRa in the growth of CCA, QBC939, MZ-ChA-1, and SK-ChA-1 cells, in which elevated RXRa protein level was observed, were transfected with siRXRa or siCtrl. HCCC9810 cells with low levels of RXRa were transfected with RXRa-expression vector. Downregulation of RXRa in CCA cells decreased cell survival compared with their respective controls, whereas overexpression of RXRa in HCCC9810 cells increased cell survival (Fig. 2a) . Furthermore, the ability of QBC939, MZ-ChA-1, and SKChA-1 cells to form foci were markedly reduced after transfection with siRXRa in contrast to that with siCtrl, whereas the ability of HCCC9810 cells to form foci was significantly increased with RXRa overexpression compared to control (Fig. 2b ). The EdU assay was then applied to analyze cell proliferation. Cell proliferation was significantly decreased in siRXRa-QBC939 cells, and significantly increased in RXRaoverexpressed HCCC9810 cells (Fig. 2c) . Together, these data indicated that RXRa expression contributes to CCA cell proliferation.
Retinoid X receptor a knockdown induces CCA cell cycle arrest.
To investigate the potential mechanism by which downregula- tion of RXRa inhibited proliferation of CCA cells, cell cycle analysis was carried out to examine whether RXRa knockdown cells are arrested in a specific phase of the cell cycle. Flow cytometry results showed that RXRa knockdown induced G 1 arrest in QBC939 cells (Fig. 3a) . Quantitative PCR and Western blotting results showed that cyclin D1and cyclin E were decreased and p21 was increased in CCA cells transfected with siRXRa compared with siCtrl cells, whereas the expression of cyclin A1 and cyclin B1was comparable (Fig. 3b,c) . In contrast, overexpression of RXRa in HCCC9810 cells strongly increased cyclin D1 and cyclin E expression and significantly decreased p21 expression, whereas the other cycle-related proteins were also comparable (Fig. 3b,  d) . Furthermore, the proliferation marker proliferating cell nuclear antigen (PCNA) was upregulated by RXRa overexpression, and was downregulated by RXRa knockdown in CCA cells. These results suggested that the expression of RXRa could promote cell cycle progression.
Retinoid X receptor a knockdown inhibits activation of Wnt ⁄ b-catenin pathway. Cyclin D1, the downstream target gene of the Wnt ⁄ b-catenin signaling pathway, (19) (20) (21) (22) was regulated by RXRa (Fig. 3b,c) . Thus, we investigated whether RXRa affected the regulation of the Wnt ⁄ b-catenin signaling pathways in CCA. Western blot analysis showed that the expression of b-catenin was decreased in RXRa knockdown CCA cells, along with phosphorylation of b-catenin at ser33 ⁄ 37 was increased. Furthermore, Wnt3a-induced accumulation of bcatenin slightly decreased after transfection of RXRa siRNA (Fig. 4a) . In contrast, Wnt3a significantly increased total bcatenin, and strongly suppressed phosphorylation and degradation of b-catenin, which was strengthened by overexpression of RXRa (Fig. 4a) . Immunofluorescence results revealed that Wnt3a-induced expression of b-catenin was suppressed by RXRa knockdown, which was in line with the above Western blotting results (Fig. 4b) . Dual-luciferase reporter assays showed that RXRa knockdown significantly reduced Wnt reporter activity. In contrast, overexpression of RXRa enhanced Wnt reporter activity, which was further increased in the treatment of Wnt3a (Fig. 4c) . In addition, we examined whether b-catenin knockdown downregulated cyclin D1 expression in CCA cells. As shown in Fig. 4(d) , downregulation of b-catenin led to decrease of cyclin D1, which was not rescued by treatment with Wnt3a. Overexpression of RXRa increased cyclin D1 expression in HCCC9810 cells, which was cancelled by b-catenin knockdown (Fig. 4e) . Collectively, these results indicated that RXRa promoted CCA cell cycle progression, at least in part, through activation of the Wnt ⁄ bcatenin signaling pathway.
Retinoid X receptor a regulates PCNA and p21 expression through activation of NF-jB signaling. We reported previously that PCNA and p21 were the targets of NF-jB pathway in CCA cells. (17) We therefore investigated whether RXRa regulated PCNA and p21 through activation of the NF-jB pathway. Treatment of CCA cells with TNFa led to strong p65 activation, which was potently impaired by RXRa knockdown; phosphorylation of p65 at ser536 was strongly activated by TNFa, which was enhanced in RXRa-overexpressed cells (Fig. 5a ). Dual-luciferase reporter assays revealed that p65 reporter activity was significantly enhanced by TNFa and was suppressed by RXRa knockdown. Furthermore, activation of p65 reporter by treatment with TNFa was reduced by RXRa knockdown (Fig. 5b) . The expression of p21 was downregulated and PCNA was upregulated in the RXRa-overexpressed cells, and was reversed by BMS345541, a specific inhibitor of NF-jB (Fig. 5c ). Taken together, these results showed that RXRa might serve as a cofactor for the transduction of the NF-jB signaling pathway for regulation of PCNA and p21.
Discussion
Retinoid X receptor a plays vital genomic roles through serving as an obligatory DNA-binding partner for a number of nuclear receptors. (23) It also shows non-genomic regulatory effects, similar to retinoic acid receptor c, as we reported previously. (17) In the present study, we found that RXRa protein expression was significantly increased and was abnormally expressed in the cytoplasm of human CCA specimens, in agreement with previous findings that RXRa resides in the cytoplasm in certain cell types. (24) Overexpression of RXRa was also detected in all CCA cell lines examined in the present study. Paradoxically, RXRa expression was significantly suppressed in colorectal cancer compared with adjacent non-tumor tissues. (25) Our results concurred with previous studies regarding the expression profile of RXRa in breast cancer, prostate tumor, and thyroid tumor, (7) (8) (9) 26) indicating that the cytoplasmic localization of RXRa may be in a cell type-dependent manner. The detailed mechanisms for RXRa overexpression in CCA remain unclear. Retinoid X receptor a has been implicated in several neoplastic diseases. The most fundamental trait of cancer cells contains their ability to sustain chronic proliferation through the cell cycle. (27) Our data presented here showed that downregulation of RXRa repressed CCA cell proliferation, colony formation, and DNA synthesis in CCA cells. Knockdown of RXRa resulted in cell cycle arrest at G 1 phase through reducing the expression of cyclin D1 and cyclin E, two critical G 1 ⁄ S transition regulators, (28) paralleled with upregulation of p21, the cell cycle inhibitor. (29) In contrast, RXRa overexpression increased cyclin D1 and cyclin E expression, and suppressed p21 expression. Furthermore, RXRa upregulated the expression of the proliferation marker PCNA, (30) indicating its important role in the growth of human CCA. These results suggested a key role of RXRa in CCA proliferation.
The present study has, for the first time, explored the possible mechanisms of RXRa on regulation of CCA cell growth. We showed that RXRa activated the Wnt ⁄ b-catenin and NF-jB survival pathways to induce CCA cell growth (Fig. 5d) . It has been shown that many oncogenic factors lead to aberrant activation of the Wnt ⁄ b-catenin pathway in many types of oncogenic diseases, including CCA. (31) In the Wnt-stimulated cell, b-catenin is not targeted for degradation in the ubiquitin proteasome. Instead, it translocates to the nucleus, where it interacts with lymphoid enhancing factor ⁄ T-cell factor transcription factors to alter target gene expression so as to regulate cell proliferation and cell cycle progression. (32) The activation of Wnt ⁄ b-catenin signaling contributes to cell proliferation through upregulation of the vital cell cycle regulator cyclin D1, which was confirmed by our previous work. (33) In addition, our findings revealed that RXRa knockdown significantly reduced total b-catenin expression and increased phosphorylation of b-catenin; however, there were reverse trends of b-catenin in RXRa-overexpressed cells, indicating that RXRa might promote CCA growth through activation of the Wnt ⁄ b-catenin pathway. Our results were in agreement with the study by Xiao et al., (34) which concluded that b-catenin interacts with RXRa in cancer cells, and RXR agonists, which degrade RXRa, induce degradation of b-catenin. Our view that the oncogenic effects of RXRa can be attributed to activation of the NF-jB signaling pathway provides insight into the link between inflammation-mediated cell signaling and regulation of RXRa. Previous studies showed that NF-jB p65 directly interacts with the DNA-binding domain of RXRa. (35) Hence, it is not surprising to show that RXRa could coactivate NF-jB transcription factor during human CCA development. Our study revealed that RXRa knockdown could regulate the expression of PCNA and p21 though suppression of the NF-jB pathway. These results suggested that the activation of the Wnt ⁄ b-catenin and NF-jB pathways is essential for RXRa-mediated cell cycle progression in CCA cells.
In conclusion, our study showed that RXRa is able to simultaneously activate the Wnt ⁄ b-catenin and NF-jB pathways to promote CCA cell proliferation and survival. Thus, RXRa might be an attractive molecular target for drug development in treatment of CCA. Our findings are potentially beneficial for the future development of novel therapeutic approaches against CCA.
